HighTower Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
HighTower Advisors's REGN Position: Q2 2026 in Review
HighTower Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 9.7% in Q2 2026, buying an estimated $3.9M and bringing the position to 64,650 shares worth $40.3M. The position accounts for 0.04% of the portfolio, ranked #433.
HighTower Advisors first reported a position in REGN in Q4 2013 and has held it in 51 quarters since. The position peaked at $45.5M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- HighTower Advisors held 64,650 shares of Regeneron Pharmaceuticals worth $40.3M as of Q2 2026.
- HighTower Advisors bought 5,725 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.9M.
- Regeneron Pharmaceuticals made up 0.04% of HighTower Advisors's portfolio in Q2 2026, its #433 holding.
- HighTower Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 51 quarters since.
- HighTower Advisors's Regeneron Pharmaceuticals position peaked at $45.5M in Q1 2026.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.